Published May 26, 2023
| Version v1
Dataset
Open
RNAseq analysis of Elafibranor and S217879 effects on human PCLS with MAFLD
Authors/Creators
- 1. Université Paris Cité, Inserm, Centre de recherche sur l'inflammation, F-75018 Paris, France
Description
Oxidative stress triggers nonalcoohlic steatohepatitis (NASH) and liver fibrosis. Nuclear-erythroid-2-Related Factor 2 (NRF2) is the master regulation of the anti-oxidant response. In this study, we tested the therapeutic potential of a new NRF2 activator (S217879) in Precision Cut Liver Slices (PCLS) derived from the liver of patients with metabolic associated fatty liver disease (MAFLD), and compared its effects to those of the well-known PPARa/d agonist, Elafibranor.